Swiss National Bank
TGTX icon

Swiss National Bank’s TG Therapeutics TGTX Stock Holding History

Swiss National Bank’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.3M Sell
296,700
-1,700
-0.6% -$69.6K 0.01% 787
2026
Q1 		$9.91M Buy
298,400
+1,200
+0.4% +$35.8K 0.01% 958
2025
Q4 		$8.86M Buy
297,200
+4,900
+2% +$160K 0.01% 1035
2025
Q3 		$10.6M Buy
292,300
+7,100
+2% +$234K 0.01% 932
2025
Q2 		$10.3M Sell
285,200
-1,300
-0.5% -$48.4K 0.01% 907
2025
Q1 		$11.3M Sell
286,500
-2,800
-1% -$94.2K 0.01% 838
2024
Q4 		$8.71M Buy
289,300
+2,700
+0.9% +$77.5K 0.01% 1013
2024
Q3 		$6.7M Sell
286,600
-2,000
-0.7% -$43.7K ﹤0.01% 1147
2024
Q2 		$5.13M Buy
288,600
+4,500
+2% +$71.8K ﹤0.01% 1262
2024
Q1 		$4.32M Buy
284,100
+1,500
+0.5% +$23.9K ﹤0.01% 1382
2023
Q4 		$4.83M Sell
282,600
-29,400
-9% -$342K ﹤0.01% 1311
2023
Q3 		$2.61M Buy
312,000
+9,300
+3% +$130K ﹤0.01% 1675
2023
Q2 		$7.52M Buy
302,700
+4,700
+2% +$121K 0.01% 1058
2023
Q1 		$4.48M Sell
298,000
-35,200
-11% -$535K ﹤0.01% 1346
2022
Q4 		$3.94M Buy
333,200
+7,800
+2% +$56.6K ﹤0.01% 1460
2022
Q3 		$1.93M Buy
325,400
+5,500
+2% +$36.1K ﹤0.01% 1896
2022
Q2 		$1.36M Buy
319,900
+32,600
+11% +$204K ﹤0.01% 2179
2022
Q1 		$2.73M Buy
287,300
+20,100
+8% +$233K ﹤0.01% 1851
2021
Q4 		$5.08M Buy
267,200
+1,500
+0.6% +$38.9K ﹤0.01% 1452
2021
Q3 		$8.84M Buy
265,700
+7,500
+3% +$232K 0.01% 1064
2021
Q2 		$10M Buy
258,200
+17,900
+7% +$703K 0.01% 1018
2021
Q1 		$11.6M Buy
240,300
+11,200
+5% +$538K 0.01% 917
2020
Q4 		$11.9M Buy
229,100
+5,100
+2% +$172K 0.01% 839
2020
Q3 		$5.99M Buy
224,000
+48,300
+27% +$1.11M ﹤0.01% 1064
2020
Q2 		$3.42M Buy
175,700
+1,900
+1% +$30.6K ﹤0.01% 1380
2020
Q1 		$1.71M Buy
173,800
+10,500
+6% +$133K ﹤0.01% 1550
2019
Q4 		$1.81M Buy
163,300
+9,900
+6% +$75.3K ﹤0.01% 1784
2019
Q3 		$861K Buy
153,400
+12,900
+9% +$89.9K ﹤0.01% 2131
2019
Q2 		$1.22M Buy
140,500
+23,300
+20% +$176K ﹤0.01% 2008
2019
Q1 		$942K Hold
117,200
– – ﹤0.01% 2091
2018
Q4 		$481K Buy
117,200
+8,300
+8% +$41.2K ﹤0.01% 2366
2018
Q3 		$610K Buy
108,900
+12,700
+13% +$145K ﹤0.01% 2358
2018
Q2 		$1.26M Hold
96,200
– – ﹤0.01% 2019
2018
Q1 		$1.37M Buy
96,200
+6,900
+8% +$88.2K ﹤0.01% 1895
2017
Q4 		$732K Hold
89,300
– – ﹤0.01% 2261
2017
Q3 		$1.06M Buy
89,300
+10,100
+13% +$115K ﹤0.01% 2030
2017
Q2 		$796K Hold
79,200
– – ﹤0.01% 2188
2017
Q1 		$923K Buy
79,200
+12,600
+19% +$90.4K ﹤0.01% 2080
2016
Q4 		$310K Hold
66,600
– – ﹤0.01% 2514
2016
Q3 		$515K Hold
66,600
– – ﹤0.01% 2342
2016
Q2 		$404K Buy
66,600
+9,900
+17% +$80.5K ﹤0.01% 2448
2016
Q1 		$466K Buy
56,700
+11,100
+24% +$97.1K ﹤0.01% 2344
2015
Q4 		$544K Hold
45,600
– – ﹤0.01% 2211
2015
Q3 		$460K Buy
45,600
+10,700
+31% +$159K ﹤0.01% 2214
2015
Q2 		$579K Hold
34,900
– – ﹤0.01% 2154
2015
Q1 		$540K Buy
34,900
+10,600
+44% +$160K ﹤0.01% 2139
2014
Q4 		$385K Buy
+24,300
New +$316K ﹤0.01% 2312

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Swiss National Bank's TGTX Position: Q2 2026 in Review

Swiss National Bank reduced its TG Therapeutics (TGTX) stake by 0.57% in Q2 2026, selling an estimated $69.6K and leaving 296,700 shares worth $16.3M. The position accounts for 0.01% of the portfolio, ranked #787.

Swiss National Bank first reported a position in TGTX in Q4 2014 and has held it in 47 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Swiss National Bank held 296,700 shares of TG Therapeutics worth $16.3M as of Q2 2026.
  • Swiss National Bank sold 1,700 TG Therapeutics shares in Q2 2026, an estimated $69.6K.
  • TG Therapeutics made up 0.01% of Swiss National Bank's portfolio in Q2 2026, its #787 holding.
  • Swiss National Bank first reported a position in TG Therapeutics in Q4 2014 and has held it in 47 quarters since.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.